Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RENESE-R vs ALDORIL D50
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Thiazide diuretic; inhibits sodium-chloride symporter in distal convoluted tubule, reducing sodium and water reabsorption.
Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.
Edema due to congestive heart failure,Mild to moderate hypertension
Hypertension (first-line or second-line therapy),Hypertensive urgency (off-label)
Initial: 5 mg orally once daily, increased as needed to 10 mg once daily; maximum 10 mg/day.
1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.
Terminal elimination half-life: 13-16 hours; clinical context: supports once-daily dosing
3–6 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for sustained blood pressure control; prolonged in renal impairment.
Metabolized by liver (CYP450) to active metabolite; excreted in feces (65%) and urine (35%).
Methyldopa is extensively metabolized in the liver via conjugation and O-methylation, with involvement of catechol-O-methyltransferase (COMT). Hydrochlorothiazide is not extensively metabolized; it is eliminated largely unchanged by the kidneys.
Renal: 50% unchanged; fecal: 0%; biliary: 0%
Renal: 50% as unchanged drug and 20% as metabolites; biliary/fecal: ~25% (as metabolites); total renal clearance accounts for ~70% of elimination.
80-90% bound to plasma proteins, primarily albumin
~20% bound to albumin; minimal binding to other plasma proteins.
0.2-0.3 L/kg; indicates distribution mainly in extracellular fluid
0.2–0.3 L/kg (moderately low Vd, indicating limited extravascular distribution and predominantly plasma water distribution).
Oral: 70-80%
Oral: 30–40% (due to extensive first-pass metabolism); IV: 100%.
GFR 30-50 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Contraindicated if GFR < 30 m L/min; for GFR 30-50 m L/min: reduce dose and monitor electrolytes.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and monitor; Class C: contraindicated.
Not approved for use in pediatric patients; safety and efficacy not established.
Not recommended; inadequate safety data.
Initiate at 2.5 mg orally once daily; use caution due to increased sensitivity to electrolyte disturbances and hypotension.
Start with 1 tablet (hydrochlorothiazide 12.5 mg + methyldopa 125 mg) once daily; increase slowly; monitor for hypotension and electrolyte imbalance.
No FDA boxed warning.
None
May cause hypokalemia and hypomagnesemia,Can precipitate hyperuricemia and gout,May increase serum calcium,Use with caution in diabetes (may increase blood glucose),Photosensitivity reactions reported,Sulfonamide allergy: possible cross-reactivity
Sedation and drowsiness common; avoid driving or hazardous activities. Risk of Coombs-positive hemolytic anemia with methyldopa (discontinue if anemia develops). Hepatotoxicity and liver function abnormalities (discontinue if jaundice occurs). Orthostatic hypotension; caution in volume-depleted patients. Electrolyte imbalances (particularly hypokalemia, hyponatremia) with hydrochlorothiazide; monitor serum electrolytes. Sulfonamide cross-sensitivity possible. Exacerbation of systemic lupus erythematosus. Avoid abrupt withdrawal of methyldopa (may cause rebound hypertension).
Anuria,Hypersensitivity to sulfonamides or thiazides,Severe renal impairment (creatinine clearance <30 m L/min),Hepatic coma or pre-coma
Active hepatic disease (cirrhosis, hepatitis) associated with methyldopa therapy; previous methyldopa-induced liver disorders. Anuria or hypersensitivity to thiazide diuretics or sulfonamide-derived drugs. Concomitant use with MAO inhibitors. Severe renal impairment (creatinine clearance <30 m L/min) or electrolyte depletion due to hydrochlorothiazide. Concurrent lithium therapy (risk of lithium toxicity).
Avoid excessive salt intake as it can reduce the antihypertensive effect. Limit alcohol consumption, which may enhance orthostatic hypotension. High-potassium foods (e.g., bananas, oranges, spinach) are generally safe but monitor potassium levels as thiazides can cause hypokalemia; supplement potassium if indicated. Grapefruit juice has no known interaction with this combination.
Avoid potassium supplements or salt substitutes containing potassium without consulting doctor. Limit alcohol intake. Avoid excessive grapefruit juice. Maintain adequate potassium intake through diet to prevent hypokalemia.
Renese-R (polythiazide) is a thiazide diuretic. Use in pregnancy, especially during the first and second trimesters, is associated with an increased risk of fetal or neonatal jaundice, thrombocytopenia, and possible other adverse reactions that have occurred in adults. Because thiazides cross the placental barrier and appear in cord blood, use during the third trimester may cause electrolyte disturbances, hypoglycemia, and other effects. The drug should be used only if clearly needed and if the potential benefit justifies the potential risk to the fetus.
Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester may cause fetal/neonatal effects including electrolyte disturbances, jaundice, thrombocytopenia, and possible fetal growth restriction. Methyldopa has not shown teratogenicity. Aldoril D50 (M 500mg/HCTZ 50mg) is not recommended during pregnancy, especially after first trimester.
Thiazides are excreted in human milk in small amounts. There is no published M/P ratio for polythiazide specifically; however, based on thiazide class, the M/P ratio is approximately 0.1-0.5. Breastfeeding is generally discouraged due to potential for adverse effects in the infant, including electrolyte imbalance and thrombocytopenia. Alternative agents are preferred, especially in high-dose therapy or when monitoring is not feasible.
Both methyldopa and HCTZ are excreted in breast milk. Methyldopa M/P ratio approximately 1.0; HCTZ M/P ratio variable, small amounts. Use during breastfeeding may suppress lactation due to HCTZ diuretic effect. Monitor infant for signs of hypotension, electrolyte imbalance. Caution recommended; use only if clearly needed.
Pregnancy may alter pharmacokinetics of thiazides due to increased plasma volume and renal blood flow. Dose adjustments are not well established; however, polythiazide should be used at the lowest effective dose to avoid excessive diuresis and electrolyte imbalances. If used, monitor maternal electrolytes and renal function closely. The dose may need to be reduced if signs of hypovolemia or electrolyte abnormalities develop. Postpartum, consider dose readjustment as plasma volume normalizes.
Pregnancy-induced increase in plasma volume may reduce effectiveness of HCTZ, requiring dose adjustment. Methyldopa pharmacokinetics not significantly altered; however, increased clearance in pregnancy may require higher doses. In preeclampsia, dose adjustments may be needed. Avoid HCTZ in pregnancy if possible.
Renese-R is a fixed-dose combination of polythiazide, a thiazide diuretic, and reserpine, a Rauwolfia alkaloid antihypertensive. Watch for hypokalemia, especially in patients on digoxin. Reserpine can cause significant bradycardia and depression; avoid in patients with history of depression. Discontinue at least 2 weeks before electroconvulsive therapy. Monitor for orthostatic hypotension, especially when used with other antihypertensives.
ALDORIL D50 combines methyldopa and hydrochlorothiazide. Monitor for orthostatic hypotension, especially in volume-depleted patients. May cause positive Coombs test, hemolytic anemia, and lupus-like syndrome. Avoid in pheochromocytoma. Use caution in hepatic disease.
Take this medication exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,Avoid alcohol and standing up quickly from lying or sitting positions to prevent dizziness.,Report symptoms of depression, severe drowsiness, or slow heartbeat to your doctor immediately.,You may need to have regular blood tests to monitor potassium levels and kidney function.,This medication can cause increased sensitivity to sunlight; use sunscreen and protective clothing.,Do not stop taking this drug abruptly without consulting your doctor.
Take exactly as prescribed; do not skip doses or double up.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Report unexplained fever, jaundice, or dark urine immediately.,Avoid sudden discontinuation; may cause rapid increase in blood pressure.,Stay hydrated but do not overhydrate; monitor for signs of electrolyte imbalance.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RENESE-R vs ALDORIL D50, answered by our medical review team.
RENESE-R is a Antihypertensive Combination that works by Thiazide diuretic; inhibits sodium-chloride symporter in distal convoluted tubule, reducing sodium and water reabsorption.. ALDORIL D50 is a Antihypertensive Combination that works by Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RENESE-R and ALDORIL D50 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RENESE-R is: Initial: 5 mg orally once daily, increased as needed to 10 mg once daily; maximum 10 mg/day.. The standard adult dose of ALDORIL D50 is: 1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RENESE-R and ALDORIL D50 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RENESE-R is classified as Category C. Renese-R (polythiazide) is a thiazide diuretic. Use in pregnancy, especially during the first and second trimesters, is associated with an increased risk of fetal or neonatal jaund. ALDORIL D50 is classified as Category C. Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.